Published today in Biomarker Insights is a new original research article by Hiroshi Furukawa, Shomi Oka, Kota Shimada, Shoji Sugii, Atsushi Hashimoto, Akiko Komiya, Naoshi Fukui, Taiichiro Miyashita, Kiyoshi Migita, Akiko Suda, Shouhei Nagaoka, Naoyuki Tsuchiya and Shigeto Tohma.  Read more about this paper below:

Title

HLA-DRB1*08:02 Is Associated with Bucillamine-Induced Proteinuria in Japanese Rheumatoid Arthritis Patients

Abstract

Background: Drug-induced proteinuria can occur in rheumatoid arthritis (RA) patients treated with d-penicillamine, gold salts, or bucillamine (Buc), and represents a drug hypersensitivity reaction. Striking associations of human leukocyte antigen (HLA) alleles with adverse reactions have recently been reported for many drugs.

Methods: We investigated the association of HLA class II with Buc-induced proteinuria (BI-Pro) in 485 Japanese RA patients treated with Buc, of whom 25 had developed BI-Pro.

Results and conclusion: This preliminary study showed a highly significant association of DRB1*08:02 with BI-Pro (P = 1.09 × 10⁻⁶, corrected P [Pc] = 1.96 × 10⁻⁵, odds ratio [OR] 25.17, 95% confidence interval [CI] 7.98–79.38). DQB1*04:02 was also significantly associated with increased risk of BI-Pro (P = 2.44 × 10⁻⁵, Pc = 2.69 × 10⁻⁴, OR 10.35, 95%CI 3.99–26.83). These findings provide useful information for promoting personalized medicine for RA.

Click here to learn more about the article, download it and comment

share on